VRTX — Vertex Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $112.92bn
- $105.68bn
- $12.00bn
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings
Vertex Q1 adjusted EPS beats estimates, revenue rises 8%
Vertex tops profit estimates as sales of new cystic fibrosis drug surge
Brief: Vertex Pharmaceuticals Q1 Adjusted EPS USD 4.47 Vs. IBES Estimate USD 4.31
Halozyme rises as Vertex signs global drug delivery tech deal
Brief: Vertex Pharmaceuticals Inc - FDA Expands Indication For Trikafta In Cf Patients Ages 2 And Older
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies
U.S. STOCKS ON THE MOVE-InspireMD, MiniMed, SoFi Technologies
Vertex rises after brokerage upgrade on kidney disease drug data
U.S. STOCKS ON THE MOVE-Rivian, Bunge, Vertex
Vertex rises on promising kidney-drug data
Street View: Vertex's kidney drug trial success boosts analysts' confidence
Brief: Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy
Vertex's kidney disease drug meets main goal in late-stage trial (updated)
Vertex's kidney disease drug meets main goal in late-stage trial
U.S. RESEARCH ROUNDUP-Brixmor Property, Mohawk Industries, UDR
Vertex Pharmaceuticals falls after Q4 profit miss
Vertex Pharma forecasts 2026 revenue in-line, expects growth in cystic fibrosis treatments
Brief: Vertex Pharmaceuticals Q4 Adjusted EPS USD 5.03 Vs. IBES Estimate USD 5.07